vTv Therapeutics (VTVT) Accounts Payables (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of Accounts Payables data on file, last reported at $6.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 62.75% year-over-year to $6.8 million; the trailing twelve-month figure through Mar 2026 stood at $6.8 million (up 62.75% YoY), and the FY2025 full-year result was $6.6 million, up 30.44% from the prior year.
• Accounts Payables advanced to $6.8 million in Q1 2026, from $6.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $12.5 million in Q1 2022 to a low of $4.2 million in Q1 2025.
• A 5-year average of $7.8 million and a median of $7.3 million in 2022 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 151.24% in 2022 and tumbled 52.0% in 2025, its largest moves.
• Tracing VTVT's Accounts Payables over 5 years: stood at $7.3 million in 2022, then jumped by 40.05% to $10.2 million in 2023, then slumped by 50.92% to $5.0 million in 2024, then soared by 30.44% to $6.6 million in 2025, then advanced by 4.03% to $6.8 million in 2026.
• Business Quant data shows VTVT's Accounts Payables at $6.8 million in Q1 2026, $6.6 million in Q4 2025, and $9.8 million in Q3 2025.